Literature DB >> 11096540

Post-Myocardial Infarction Pericarditis.

.   

Abstract

Post-myocardial infarction pericarditis occurs in approximately 5% to 6% of patients who receive thrombolytic agents. It should be suspected in any patient with pleuropericardial pain. A pericardial friction rub may or may not be present. Differentiation of pericarditis from recurrent angina may be difficult, but a careful history and evaluation of serial electrocardiograms can help distinguish the two entities. Dressler's syndrome, pericarditis that occurs at least 1 week following myocardial infarction, is now exceedingly rare. Most cases of pericarditis have a benign course; however, because pericarditis is associated with larger infarcts, overall long-term mortality rate is increased. Rare complications include hemopericardium, cardiac tamponade, and constrictive pericarditis. Therapy is directed toward relief of pain, which usually responds well to nonsteroidal anti- inflammatory agents (eg, aspirin or ibuprofen).

Entities:  

Year:  2000        PMID: 11096540     DOI: 10.1007/s11936-996-0009-7

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  16 in total

1.  The post-myocardial-infarction syndrome: a report on forty-four cases.

Authors:  W DRESSLER
Journal:  AMA Arch Intern Med       Date:  1959-01

Review 2.  Echocardiographically guided pericardiocentesis: evolution and state-of-the-art technique.

Authors:  T S Tsang; W K Freeman; L J Sinak; J B Seward
Journal:  Mayo Clin Proc       Date:  1998-07       Impact factor: 7.616

3.  Pericarditis complicating acute myocardial infarction: incidence of complications and significance of electrocardiogram on admission.

Authors:  E Lichstein; H M Liu; P Gupta
Journal:  Am Heart J       Date:  1974-02       Impact factor: 4.749

Review 4.  Pericardial involvement in acute myocardial infarction in the post-thrombolytic era: clinical meaning and value.

Authors:  E Correale; A P Maggioni; S Romano; V Ricciardiello; R Battista; E Santoro
Journal:  Clin Cardiol       Date:  1997-04       Impact factor: 2.882

5.  Indomethacin-induced scar thinning after experimental myocardial infarction.

Authors:  H Hammerman; R A Kloner; F J Schoen; E J Brown; S Hale; E Braunwald
Journal:  Circulation       Date:  1983-06       Impact factor: 29.690

6.  Electrocardiographic diagnosis of postinfarction regional pericarditis. Ancillary observations regarding the effect of reperfusion on the rapidity and amplitude of T wave inversion after acute myocardial infarction.

Authors:  P B Oliva; S C Hammill; W D Edwards
Journal:  Circulation       Date:  1993-09       Impact factor: 29.690

Review 7.  The postcardiac injury syndromes.

Authors:  A H Khan
Journal:  Clin Cardiol       Date:  1992-02       Impact factor: 2.882

8.  Therapy of symptomatic pericarditis after myocardial infarction: retrospective and prospective studies of aspirin, indomethacin, prednisone, and spontaneous resolution.

Authors:  J Berman; C I Haffajee; J S Alpert
Journal:  Am Heart J       Date:  1981-06       Impact factor: 4.749

9.  Psotcardiotomy syndrome: pathogenesis and management.

Authors:  M H Lessof
Journal:  Hosp Pract       Date:  1976-09

10.  The clinical distinction between regional postinfarction pericarditis and other causes of postinfarction chest pain: ancillary observations regarding the effect of lytic therapy upon the frequency of postinfarction pericarditis, postinfarction angina, and reinfarction.

Authors:  P B Oliva; S C Hammill
Journal:  Clin Cardiol       Date:  1994-09       Impact factor: 2.882

View more
  1 in total

1.  The proteoglycan biglycan enhances antigen-specific T cell activation potentially via MyD88 and TRIF pathways and triggers autoimmune perimyocarditis.

Authors:  Zoran V Popovic; Shijun Wang; Maria Papatriantafyllou; Ziya Kaya; Stefan Porubsky; Maria Meisner; Mahnaz Bonrouhi; Sven Burgdorf; Marian F Young; Liliana Schaefer; Hermann-Josef Gröne
Journal:  J Immunol       Date:  2011-11-16       Impact factor: 5.422

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.